Literature DB >> 15195131

Variable definitions influence the reporting of biochemical failure rates.

E E Cherullo1, L E Ponsky, K K Goyal, F Pasquallotto, C D Zippe.   

Abstract

The purpose of this study was to assess how the reporting of biochemical failure (BF) rates would be affected by the application of three different definitions. Three hundred and fifteen men with localized prostate cancer underwent I-125 brachytherapy (n=109), conformal three-dimensional radiation therapy (n=99), or radical prostatectomy (n=107). No patient received adjuvant or neoadjuvant hormone therapy in this study. BF rates at 12, 24 and 36 months were assessed using three definitions: (1) prostate-specific antigen (PSA) nadir >0.5 ng/ml; (2) PSA rise by 0.5 ng/ml; and (3) three consecutive PSA rises. Median follow-up for the brachytherapy group, external beam radiotherapy group, and the radical prostatectomy group was 27, 30 and 36 months respectively. The applied definition influenced reporting of failure rates in two of the three groups. I-125 brachytherapy group: BF rates at 24 months: 46%-definition 1, 35%-definition 2, and 4%-definition 3 (P<0.05). Radiation therapy group: BF rates at 24 months: 39%-definition 1, 17%-definition 2 and 3%-definition 3 (P<0.05). No patient in the radical prostatectomy group had a BF by any applied definition. A more universal definition of BF is needed to compare the efficacy of treatments for localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15195131     DOI: 10.1038/sj.pcan.4500545

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  1 in total

1.  The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Takuya Owari; Shunta Hori; Yosuke Morizawa; Yasushi Nakai; Takeshi Inoue; Satoshi Anai; Kazumasa Torimoto; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  Prostate Int       Date:  2018-05-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.